Hui Lin Cheng1, Alex Molassiotis1, Anthony Kwun To Leung2, Kam Hung Wong2. 1. School of Nursing, The Hong Kong Polytechnic University, Hong Kong, Hong Kong, China. 2. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong, China.
Abstract
BACKGROUND: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. METHODS: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. RESULTS: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. CONCLUSIONS: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.
BACKGROUND: Docetaxel-induced peripheral neuropathy (PN) is typically manifested as sensory and motor neuropathy. This study aimed to investigate the incidence, duration, and risk factors of sensory and motor PN and their impact on health-related quality of life (HRQOL) among breast cancer (BC) patients during the first year since starting docetaxel-based chemotherapy. METHODS: We reported a secondary analysis of longitudinal data on docetaxel-induced PN and HRQOL among 127 BC patients. RESULTS: Cumulative incidence rates of motor and sensory PN were 31.5 and 21.3%, while the median durations of motor and sensory PN were 6 and 13 weeks. A consistently significant risk factor for both PNs was a cumulative docetaxel dose of >300 mg/m2. A significant interaction between sensory PN and time was found for physical and social functioning, while a significant motor PN and time interaction effect was identified for physical functioning only. CONCLUSIONS: Motor PN was more common than sensory PN in BC patients treated with docetaxel. Both types of PN had a significant impact on physical functioning.
Authors: Hanna Bandos; Joy Melnikow; Donna R Rivera; Sandra M Swain; Keren Sturtz; Louis Fehrenbacher; James L Wade; Adam M Brufsky; Thomas B Julian; Richard G Margolese; Edward C McCarron; Patricia A Ganz Journal: J Natl Cancer Inst Date: 2018-02-01 Impact factor: 13.506
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: Susana Pereira; Filipa Fontes; Teresa Sonin; Teresa Dias; Maria Fragoso; José M Castro-Lopes; Nuno Lunet Journal: Support Care Cancer Date: 2015-09-18 Impact factor: 3.603
Authors: G Cavaletti; D R Cornblath; I S J Merkies; T J Postma; E Rossi; B Frigeni; P Alberti; J Bruna; R Velasco; A A Argyriou; H P Kalofonos; D Psimaras; D Ricard; A Pace; E Galiè; C Briani; C Dalla Torre; C G Faber; R I Lalisang; W Boogerd; D Brandsma; S Koeppen; J Hense; D Storey; S Kerrigan; A Schenone; S Fabbri; M G Valsecchi; A Mazzeo; A Pace; A Pessino; A Schenone; A Toscano; A A Argyriou; B Brouwer; B Frigeni; B Piras; C Briani; C Dalla Torre; C Dominguez Gonzalez; C G Faber; C Tomasello; D Binda; D Brandsma; D Cortinovis; D Psimaras; D Ricard; D Storey; D R Cornblath; E Galiè; E Lindeck Pozza; E Rossi; E K Vanhoutte; F Lanzani; F Pastorelli; G Altavilla; G Cavaletti; G Granata; H P Kalofonos; I Ghignotti; I S J Merkies; J Bruna; J Hense; J J Heimans; L Mattavelli; L Padua; L Reni; M Bakkers; M Boogerd; M Campagnolo; M Cazzaniga; M Eurelings; M Leandri; M Lucchetta; M Penas Prado; M Russo; M G Valsecchi; M L Piatti; P Alberti; P Bidoli; R Grant; R Plasmati; R Velasco; R I Lalisang; R J Meijer; S Fabbri; S G Dorsey; S Galimberti; S Kerrigan; S Koeppen; T J Postma; W Boogerd; W Grisold Journal: Ann Oncol Date: 2012-08-21 Impact factor: 32.976
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Michael D Stubblefield; Harold J Burstein; Allen W Burton; Christian M Custodio; Gary E Deng; Maria Ho; Larry Junck; G Stephen Morris; Judith A Paice; Sudhakar Tummala; Jamie H Von Roenn Journal: J Natl Compr Canc Netw Date: 2009-09 Impact factor: 11.908
Authors: Elisa Aranda; José A Teruel; Antonio Ortiz; María Dolores Pérez-Cárceles; Francisco J Aranda Journal: J Membr Biol Date: 2022-02-17 Impact factor: 2.426